Table 1. . Comparison of overall response rate, progression-free survival and overall survival rates for monotherapy and combination therapy.
| Variable | Vemurafenib monotherapy (BRIM-3 [28,39]) | Dabrafenib monotherapy (BREAK-3 [36–38]) | Dabrafenib/trametinib (Combi-D [44]) | Dabrafenib/trametinib (Combi-V [45]) | Vemurafenib/cobimetinib (CoBRIM [46]) |
|---|---|---|---|---|---|
| Patients (n) | 337† | 187‡ | 211§ | 352¶ | 247# |
| ORR (%) | 48 | 50 | 67 | 64 | 68 |
| PFS (months) | 6.9 | 6.9 | 9.3 | 11.4 | 9.9 |
| OS | All genotypes: 13.6 months; BRAF V600E: 13.3 months [39]; BRAF V600K: 14.5 months | V600E only 20.0 months | 25.1 months | 72% (at 12 months) | 81% (at 9 months) |
†Number of vemurafenib patients treated.
‡Number of dabrafenib patients treated.
§Number of dabrafenib/trametinib patients treated.
¶Number of dabrafenib/trametinib patients treated.
#Number of vemurafenib/cobimetinib patients treated.
ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival.